Current therapy of lupus nephritis. Which is the best option?
Renal involvement in systemic lupus erythematosus (SLE) is an important cause of morbidity and mortality, reaching a prevalence of 39% during the course of the disease. Currently, the therapy for severe lupus nephritis is based on the use of high-dose corticosteroids and immunosuppressive drugs, being traditionally cyclophosphamide the most frequently used agent. Recent studies have demonstrated the efficacy of mycophenolate mofetil as induction therapy for lupus nephritis. Azathioprine, a safe drug during pregnancy, has not been demonstrated to be as effective as mycophenolate or cyclophosphamide as induction therapy, although it is an effective drug for maintenance of remission.
Silva-Fernández
L
L
Servicio de Reumatología, Hospital Universitario Puerta de Hierro, Madrid, Spain. lsilvaf.hpth@salud.madrid.org
Andreu-Sánchez
J L
JL
Ginzler
E M
EM
D006801:Humans; D008181:Lupus Nephritis / Q000188:drug therapy*